Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

References

• Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F. WHO classification of tumours of soft tissue and bone. IARC Press; 2013.
   Google Scholar
• Toulmonde M, Penel N, Adam J, Chibon C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, et al. Use of PD-1 targeting, macrophage infiltration, and ido pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncology. 2018;4(1):93–10. doi:10.1001/jamaoncol.2017.1617.
   PubMed Web of Science ®Google Scholar
• Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123(17):3285–3290. doi:10.1002/cncr.30738.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;17: 30624–1.
   Google Scholar
• D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–426. doi:10.1016/S1470-2045(18)30006-8.
   PubMed Web of Science ®Google Scholar
• Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5(1):100–108. doi:10.1186/s40425-017-0301-y.
   PubMed Web of Science ®Google Scholar
• Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M. First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncoimmunology. 2017;8(8):e1338235. doi:10.1080/2162402X.2017.1338235.
   Web of Science ®Google Scholar
• Gounder MM, Ali SM, Robinson V, Bailey M, Ferraro R, Patel NM, Krishnan A, Millis SZ, Dickson MA, D’Angelo SP, et al. Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma. J Clin Oncol. 2017;35(15_suppl):11001. suppl;abstr 11001. doi:10.1200/JCO.2017.35.15_suppl.11001.
   Web of Science ®Google Scholar
• Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001;61(18):6868–6875.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;3(3):357–365. doi:10.1016/j.humpath.2014.11.001.
   Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;6230(6230):124–128. doi:10.1126/science.aaa1348.
   Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950–965.e28. doi:10.1016/j.cell.2017.10.014.
   PubMed Web of Science ®Google Scholar
• Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015;14(14):12234–12247. doi:10.18632/oncotarget.3498.
   Google Scholar
• Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma. 2015;547460.
   Google Scholar
• Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;17(17):3291–3304. doi:10.1002/cncr.30726.
   Web of Science ®Google Scholar
• Bertucci F, Finetti P, Perrot D, Leroux A, Collin F, Le Cesne A. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology. 2017;3(3):e1278100. doi:10.1080/2162402X.2016.1278100.
   Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;7528(7528):568–571. doi:10.1038/nature13954.
   Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology. 2016;6(1):e1137418. doi:10.1080/2162402X.2015.1137418.
   PubMed Web of Science ®Google Scholar
• Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17(6):700–707. doi:10.1038/nm.2366.
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Zeng S, Vitiello GA, Seifert AM, Medina BD, Beckman MJ. Macrophages and CD8+T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors. Cancer Immunol Res. 2018;6(4):434–447. doi:10.1158/2326-6066.CIR-17-0345.
   PubMed Web of Science ®Google Scholar
• Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69(8):3563–3569. doi:10.1158/0008-5472.CAN-08-3807.
   PubMed Web of Science ®Google Scholar
• Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556–560. doi:10.1038/s41586-019-1906-8.
   PubMed Web of Science ®Google Scholar
• Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+T cells. Cancer Res. 2012;72(23):6130–6141. doi:10.1158/0008-5472.CAN-12-2409.
   PubMed Web of Science ®Google Scholar
• Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res. 2012;72(20):5240–5249. doi:10.1158/0008-5472.CAN-12-2271.
   PubMed Web of Science ®Google Scholar
• Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One. 2011;6(1):e14611. doi:10.1371/journal.pone.0014611.
   PubMed Web of Science ®Google Scholar
• Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123(17):3291–3304. doi:10.1002/cncr.30726.
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407. doi:10.3389/fimmu.2016.00407.
   PubMed Web of Science ®Google Scholar
• Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 2014;189(7):832–844. doi:10.1164/rccm.201309-1611OC.
   PubMed Web of Science ®Google Scholar
• Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C. Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer. Oncoimmunology. 2016;6(1):e1257452. doi:10.1080/2162402X.2016.1257452.
   PubMed Web of Science ®Google Scholar
• Bo X, Wang J, Suo T, Ni X, Liu H, Shen S, Li M, Wang Y, Liu H, Xu J, et al. Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients. BMC Cancer. 2018;18(1):313. doi:10.1186/s12885-018-4220-1.
   PubMed Web of Science ®Google Scholar
• Lopes JM, Hannisdal E, Bjerkehagen B, Bruland OS, Danielsen HE, Pettersen EO, Sobrinho-Simões M, Nesland JM. Synovial sarcoma. evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Anal Cell Pathol. 1998;16(1):45–62. doi:10.1155/1998/545906.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55–61. doi:10.1016/j.biopha.2017.08.003.
   PubMed Web of Science ®Google Scholar
• Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016;13(12):e1002194. doi:10.1371/journal.pmed.1002194.
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao Y-W, Wei Y-Q. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7(12):e50946. doi:10.1371/journal.pone.0050946.
   PubMed Web of Science ®Google Scholar
• Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T, Sasaki T, Yamagishi T, Umezu H, Endo N, et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci. 2018;09(10):3043–3054. doi:10.1111/cas.13769.
   Web of Science ®Google Scholar
• Ménétrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of IL-6 and M-CSF. Blood. 1998;92(12):1–11. doi:10.1182/blood.V92.12.4778.
   PubMed Web of Science ®Google Scholar
• Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37–42. doi:10.1002/ijc.2910330108.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466–1478. doi:10.1043/1543-2165(2006)130[1466:GSTROM]2.0.CO;2.
   PubMed Web of Science ®Google Scholar
• Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, et al. NETSARC/RREPS and French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017;11(11):2852–2859. doi:10.1093/annonc/mdx484.
   Web of Science ®Google Scholar
• Dantas-Barbosa C, Lesluyes T, Loarer FL, Chibon F, Treilleux I, Coindre JM, Meeus P, Brahmi M, Bally O, Ray-Coquard I, et al. Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. Br J Cancer. 2017;117(12):1787–1797. doi:10.1038/bjc.2017.354.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar